Likelihood of pregnancy following artificial insemination by donor (AID) or in vitro fertilization (IVF) was not negatively affected by using sperm that had been cryopreserved for up to 15 years, according to a study from China.
Imaging of prostate specific membrane antigen (PSMA) targeted radiotracers appears to be useful in detecting biochemically recurrent prostate cancer at low prostate-specific antigen (PSA) levels, suggest the results of a systematic review and meta-analysis.
In addition to the known evils of maternal smoking during pregnancy on the sons' semen quality, prenatal exposure to paternal smoking can also be harmful, according to data from the large Danish National Birth Cohort (DNBC) presented at the ESHRE 2019 Meeting.
Infection could be a risk factor for stroke, with the risk for ischaemic stroke particularly high among individuals who had a urinary tract infection (UTI) 7 days prior, according to a recently published report.
The four-valent ExPEC4V vaccine which contains O-antigens from the Escherichia coli (E. coli) serotypes O1A, O2, O6A, and O25B was well tolerated and immunogenic against extra-intestinal pathogenic E. coli (ExPEC) infections, according to the phase II US-based ESTELLA trial.
Adding apalutamide to androgen-deprivation therapy (ADT) significantly extends radiographic progression-free survival (rPFS) and overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with ADT alone, the TITAN* study shows.
Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.
The novel antibody-drug conjugate enfortumab vedotin showed promising clinical activity in patients with advanced and metastatic urothelial cancer for whom there is a high unmet need, according to the EV-201 study presented at the ASCO 2019 Meeting.
The 17th Urological Association of Asia Congress will take place from the 7 to 10 August 2019 at Kuala Lumpur Convention Centre. This year, the theme is ‘Unifying Asia thru Urology’ and will be the second time Malaysia plays host to the prestigious regional congress, with the last being 2002. Close to 2,000 participants are expected for the congress, which will be one of the most inclusive urological congresses to date. MIMS Doctor spoke to Congress Chairman Dato’ Dr Rohan Malek and Dato’ Dr Selvalingam Sothilingam, president of the Malaysian Urological Association (MUA) for their thoughts on the upcoming conference.
New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.